4-(3-苯基丙基)吡啶1-氧化物 | 84824-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(3-苯基丙基)吡啶1-氧化物
• 英文名称: 4-(3-phenylpropyl)pyridine 1-oxide
• 英文别名: 4-(3-phenylpropyl)pyridine N-oxide；4-(3-phenylpropyl)pyridine-N-oxide；4-phenylpropylpyridine-N-oxide；P₃NO；4-(3-phenylpropyl)-pyridineoxide；1-oxido-4-(3-phenylpropyl)pyridin-1-ium
• CAS: 84824-92-0
• 化学式: C₁₄H₁₅NO
• mdl: MFCD00129033
• 分子量: 213.279
• InChiKey: OOFBEJNEUVLZOW-UHFFFAOYSA-N

物化性质

• 沸点：
  397.6±11.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(3-苯基丙基)吡啶1-氧化物 在 methyloxorhenium(V)(2-(mercaptomethyl)thiophenolate) triphenylphosphine 、 三苯基膦 作用下， 以 苯 为溶剂， 反应 0.3h， 以100%的产率得到4-(3-苯基丙基)吡啶
  参考文献：
  名称：

  用Ox（V）催化剂将吡啶N-氧化物高效催化转化为吡啶

  摘要：

  化合物CH（3）Re（O）（SR）（2）PPh（3）（其中（SR）（2）表示2-（巯基甲基）硫酚的二价阴离子）可催化氧原子快速有效地转移各种环取代的吡啶N-氧化物生成三苯基膦，可高产率地生产吡啶。

  DOI：

  10.1021/ol006595k
• 作为产物：
  描述：

  4-(3-苯基丙基)吡啶 在 双氧水 作用下， 以 水 、 丙酮 为溶剂， 生成 4-(3-苯基丙基)吡啶1-氧化物
  参考文献：
  名称：

  苯基丙基吡啶N-氧化物和N-甲基苯基丙基吡啶的固态结构和溶液分析

  摘要：

  比较了苯基丙基吡啶-N-氧化物和N-甲基-苯基丙基吡啶-碘化物的晶体结构，发现与溶剂分子的氢键在N-氧化物化合物中起着重要作用，而静电相互作用在控制固态取向方面起主要作用的ñ甲基化的化合物。荧光光谱和NOESY表明，与以前报道的碘化吡啶鎓相比，N氧化物不受分子内π堆积的影响，这分别由受激准分子发射和缺乏相应的交叉峰来判断。

  DOI：

  10.1002/asia.200800255
• 作为试剂：
  描述：

  茚 在 sodium hypochlorite 、 (-)-chloro((1R,2R)-4,4',6,6'-tetra-tert-butyl-2,2'-[cyclohexane-1,2-diylbis(nitrilomethylidyne)]diphenolato)manganese(III) 、 4-(3-苯基丙基)吡啶1-氧化物 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 生成 1-茚酮
  参考文献：
  名称：

  Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels

  摘要：

  Background and PurposeThe cation channel transient receptor potential canonical (TRPC) 6 has been associated with several pathologies including focal segmental glomerulosclerosis, pulmonary hypertension and ischaemia reperfusion‐induced lung oedema. We set out to discover novel inhibitors of TRPC6 channels and investigate the therapeutic potential of these agents.Experimental ApproachA library of potential TRPC channel inhibitors was designed and synthesized. Activity of the compounds was assessed by measuring intracellular Ca2+ levels. The lead compound SAR7334 was further characterized by whole‐cell patch‐clamp techniques. The effects of SAR7334 on acute hypoxic pulmonary vasoconstriction (HPV) and systemic BP were investigated.Key ResultsSAR7334 inhibited TRPC6, TRPC3 and TRPC7‐mediated Ca2+ influx into cells with IC50s of 9.5, 282 and 226 nM, whereas TRPC4 and TRPC5‐mediated Ca2+ entry was not affected. Patch‐clamp experiments confirmed that the compound blocked TRPC6 currents with an IC50 of 7.9 nM. Furthermore, SAR7334 suppressed TRPC6‐dependent acute HPV in isolated perfused lungs from mice. Pharmacokinetic studies of SAR7334 demonstrated that the compound was suitable for chronic oral administration. In an initial short‐term study, SAR7334 did not change mean arterial pressure in spontaneously hypertensive rats (SHR).Conclusions and ImplicationsOur results confirm the role of TRPC6 channels in hypoxic pulmonary vasoregulation and indicate that these channels are unlikely to play a major role in BP regulation in SHR. SAR7334 is a novel, highly potent and bioavailable inhibitor of TRPC6 channels that opens new opportunities for the investigation of TRPC channel function in vivo.

  DOI：

  10.1111/bph.13151

文献信息

• [EN] DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS<br/>[FR] ANALOGUES DE DIHYDROBENZOFURANE ET D'INDEN EN TANT QU'INHIBITEURS DE SARCOMES CARDIAQUES
  申请人：CYTOKINETICS INC

  公开号：WO2019144041A1

  公开（公告）日：2019-07-25

  Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.

  提供的是式（I）的化合物，或其药学上可接受的盐，其中A、Z、B、R1、R2、R3、G1、G2和G3如本文所定义。还提供了一种包含式（I）的化合物或其药学上可接受的盐的药学上可接受的组合物。还提供了使用式（I）的化合物或其药学上可接受的盐的方法，用于治疗心脏疾病通过心肌肌节抑制。
• α-Heteroarylation of Thioethers via Photoredox and Weak Brønsted Base Catalysis
  作者：Edwin Alfonzo、Sudhir M. Hande

  DOI：10.1021/acs.orglett.1c02151

  日期：2021.8.6

  thioethers to α-thio alkyl radicals and their addition to N-methoxyheteroarenium salts for the redox-neutral synthesis of α-heteroaromatic thioethers. Studies are consistent with a two-step activation mechanism, where oxidation of thioethers to sulfide radical cations by a photoredox catalyst is followed by α-C–H deprotonation by a weak Brønsted base catalyst to afford α-thio alkyl radicals. Further,

  我们报告了硫醚对 α-硫代烷基自由基的 C-H 活化以及它们与N-甲氧基杂芳鎓盐的加成，用于氧化还原中性合成 α-杂芳族硫醚。研究与两步活化机制一致，其中通过光氧化还原催化剂将硫醚氧化为硫化物自由基阳离子，然后通过弱 Brønsted 碱催化剂进行 α-C-H 去质子化以提供 α-硫代烷基自由基。此外，N-甲氧基杂芳鎓盐作为甲氧基自由基的来源，有助于α-硫代烷基自由基的产生和再生光氧化还原催化循环的牺牲氧化剂，发挥了额外的作用。
• MONOAMINE RE-UPTAKE INHIBITORS AND METHODS RELATING THERETO
  申请人：Pontillo Joseph

  公开号：US20060276454A1

  公开（公告）日：2006-12-07

  Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The compounds of this invention have the structure: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, W, X, Y, and Z are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts, esters and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting monoamine re-uptake in a subject in need thereof.

  单胺再摄取抑制剂，更具体地说是血清素和去甲肾上腺素再摄取抑制剂，被披露具有在男性和女性中治疗中枢或外周神经系统疾病的效用。本发明的化合物具有以下结构： 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，m，n，W，X，Y和Z如本文所定义，包括立体异构体，前药和药学上可接受的盐，酯和溶剂。还披露了含有本发明化合物的组合物与药学上可接受的载体，以及与使用该化合物抑制受需要的主体中的单胺再摄取有关的方法。
• Piperazinylpiperidine derivatives as chemokine receptor antagonists
  申请人：Xue Chu-Biao

  公开号：US20050261310A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

  本发明涉及式I的化合物：其中变量取代基在此定义，可调节或结合于趋化因子受体，如CCR5。在某些实施例中，本发明的化合物对CCR5是有选择性的。例如，这些化合物可用于治疗与趋化因子受体表达或活性相关的疾病，如炎症性疾病、免疫性疾病和病毒感染。
• Indanyl-Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them
  申请人：Bialy Laurent

  公开号：US20140378686A1

  公开（公告）日：2014-12-25

  The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

  这项发明涉及公式(I)的取代4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶，它们作为药物的用途，以及包含它们的药物制剂。公式(I)的化合物对TASK-1钾通道起作用。这些化合物特别适用于治疗或预防心房心律失常，例如心房颤动（AF）或心房扑动。